These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17539051)

  • 21. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
    Ratain MJ; Eckhardt SG
    J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
    [No Abstract]   [Full Text] [Related]  

  • 24. [Introduction and consideration of the anti-cancer drug evaluation strategy in Europe and America].
    Tang JY; Ma L; Zhang L
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):798-800. PubMed ID: 19173820
    [No Abstract]   [Full Text] [Related]  

  • 25. Researchers consider value-of-information theory for selecting trials.
    Schmidt C
    J Natl Cancer Inst; 2010 Feb; 102(3):144-6. PubMed ID: 20107161
    [No Abstract]   [Full Text] [Related]  

  • 26. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA clarifies rules for getting experimental drugs.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Apr; 99(8):584-5, 589. PubMed ID: 17440154
    [No Abstract]   [Full Text] [Related]  

  • 28. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New initiatives aim to test more cancer drugs for children.
    Brower V
    J Natl Cancer Inst; 2004 Dec; 96(24):1808-10. PubMed ID: 15601634
    [No Abstract]   [Full Text] [Related]  

  • 30. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 31. Academia given a helping hand in drug development.
    Branca MA
    Nat Rev Drug Discov; 2006 Mar; 5(3):177. PubMed ID: 16557654
    [No Abstract]   [Full Text] [Related]  

  • 32. The seamless approach to drug development in oncology.
    Pazdur R
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
    [No Abstract]   [Full Text] [Related]  

  • 33. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 34. Researchers left to guess at outcomes of most cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.
    Beitz J; Gnecco C; Justice R
    J Natl Cancer Inst Monogr; 1996; (20):7-9. PubMed ID: 8750460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I cancer trials: therapeutic research?
    Wells RJ
    Hastings Cent Rep; 2001; 31(1):4; author reply 5. PubMed ID: 11478096
    [No Abstract]   [Full Text] [Related]  

  • 37. Looking abroad: clinical drug trials.
    Hathaway CR; Manthei JR; Haas JB; Scherer CA
    Food Drug Law J; 2008; 63(3):673-81. PubMed ID: 19031667
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase I cancer trials: therapeutic research?
    Kodish E
    Hastings Cent Rep; 2001; 31(1):4-5. PubMed ID: 11478093
    [No Abstract]   [Full Text] [Related]  

  • 39. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
    Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
    Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.